India Pharma Outlook Team | Wednesday, 18 February 2026
Rx Propellant is investing USD 100 million to build a major life sciences campus in Genome Valley, strengthening Hyderabad’s position as a fast-growing global biotech hub.
The project will rise on a 12-acre site and add more than one million square feet of advanced lab and research space.
The new campus will be developed in phases over the next six years. It is designed to meet global standards and support research, development, and small-scale manufacturing for both Indian and international companies. The company’s existing facilities in Hyderabad are already fully leased, reflecting strong demand for high-quality lab infrastructure in the region.
Also Read: How Digital Maturity is Powering Pharma's GMP Evolution
With this expansion, Rx Propellant aims to address the shortage of ready-to-move research space in Genome Valley, which has become one of India’s most important biotech clusters. The campus will feature modern lab blocks, shared infrastructure, and compliance-ready facilities tailored to pharmaceutical, biotech, and life sciences firms.
Industry observers see the move as a clear signal of rising investor confidence in India’s research ecosystem. As global companies look to expand R&D operations, Hyderabad continues to attract capital, talent, and long-term infrastructure projects. The new development is expected to further boost the city’s reputation as a preferred destination for innovation in the life sciences sector.
